ACVR2A (activin A receptor type 2A) is a transmembrane serine/threonine kinase that functions as a type II receptor in the activin signaling pathway. Upon ligand binding to activin A, activin B, or inhibin A, ACVR2A forms a receptor complex with type I kinases, phosphorylating and activating downstream SMAD transcriptional regulators to control gene expression 12. The receptor promotes osteoblast differentiation and bone mineralization through SMAD-mediated signaling. ACVR2A mutations occur at elevated frequencies in non-viral hepatocellular carcinoma, particularly NASH-related HCC (10% vs 3% in other aetiologies) 3. ACVR2A functions as a tumor suppressor; its silencing increases HCC cell proliferation in vitro 3. ACVR2A deficiency promotes colorectal carcinoma progression through BMP pathway disruption 4 and drives hepatocellular carcinoma by inducing hyperglycolysis and lactate production via SMAD pathway inactivation, leading to regulatory T cell accumulation and immunotherapy resistance 5. Additionally, circular RNA derived from ACVR2A acts as a miRNA sponge to promote HCC progression 6. ACVR2A genetic variants associate with hypertensive disorders of pregnancy 7 and isolated mesiodens formation 8. These findings establish ACVR2A as a critical metabolic and immunological regulator with significant tumor suppressive functions in cancer development.